CN116390712A - 治疗偏头痛 - Google Patents

治疗偏头痛 Download PDF

Info

Publication number
CN116390712A
CN116390712A CN202180054911.0A CN202180054911A CN116390712A CN 116390712 A CN116390712 A CN 116390712A CN 202180054911 A CN202180054911 A CN 202180054911A CN 116390712 A CN116390712 A CN 116390712A
Authority
CN
China
Prior art keywords
migraine
days
weeks
atrogepam
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180054911.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·特鲁格曼
M·芬尼根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals Holdings Ireland ULC
Original Assignee
Aptalis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80003948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116390712(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharma Ltd filed Critical Aptalis Pharma Ltd
Publication of CN116390712A publication Critical patent/CN116390712A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
CN202180054911.0A 2020-07-29 2021-07-29 治疗偏头痛 Pending CN116390712A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063103353P 2020-07-29 2020-07-29
US63/103,353 2020-07-29
US202063070449P 2020-08-26 2020-08-26
US63/070,449 2020-08-26
US202063087175P 2020-10-02 2020-10-02
US63/087,175 2020-10-02
US202063092211P 2020-10-15 2020-10-15
US63/092,211 2020-10-15
US202063129362P 2020-12-22 2020-12-22
US63/129,362 2020-12-22
US202163201254P 2021-04-20 2021-04-20
US63/201,254 2021-04-20
PCT/US2021/043791 WO2022026767A1 (en) 2020-07-29 2021-07-29 Treatment of migraine

Publications (1)

Publication Number Publication Date
CN116390712A true CN116390712A (zh) 2023-07-04

Family

ID=80003948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180054911.0A Pending CN116390712A (zh) 2020-07-29 2021-07-29 治疗偏头痛

Country Status (9)

Country Link
US (2) US12090148B2 (https=)
EP (1) EP4188375A4 (https=)
JP (1) JP2023535744A (https=)
CN (1) CN116390712A (https=)
AU (1) AU2021319090A1 (https=)
BR (1) BR112023001615A2 (https=)
CA (1) CA3190176A1 (https=)
MX (1) MX2023001071A (https=)
WO (1) WO2022026767A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
WO2023055758A1 (en) * 2021-09-29 2023-04-06 Pfizer Ireland Pharmaceuticals Preventative treatment of migraine
MX2024010878A (es) * 2022-03-09 2024-09-17 Allergan Pharmaceuticals Int Ltd Tratamiento preventivo de la migra?a.

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6103260A (en) 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
AU2004222378B2 (en) 2003-03-14 2008-08-14 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin CGRP receptor antagonists
CA2519515A1 (en) 2003-03-14 2004-10-14 Merck & Co., Inc. Benodiazepine spirohydantoin cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005041869A2 (en) 2003-10-24 2005-05-12 Josef Rettenmaier & Soehne Gmbh & Co., Kg Process for co-spray drying agents with dry silicified mcc
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CA2579847A1 (en) 2004-09-13 2006-03-23 Merck & Co., Inc. Bicyclic anilide spirolactam cgrp receptor antagonists
DE102004063755A1 (de) 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
CA2599925A1 (en) 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
WO2007092642A2 (en) 2006-02-09 2007-08-16 Merck & Co., Inc. Polymer formulations of cetp inhibitors
AU2007284994B2 (en) 2006-05-09 2010-04-22 Merck Sharp & Dohme Corp. Substituted spirocyclic CGRP receptor antagonists
CA2689217C (en) 2007-06-05 2016-02-16 Merck & Co., Inc. Carboxamide heterocyclic cgrp receptor antagonists
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
WO2009065922A2 (de) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
CA2722536A1 (en) 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US20150023888A1 (en) 2008-09-05 2015-01-22 Map Pharmaceuticals, Inc. Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010139717A1 (de) 2009-06-05 2010-12-09 Boehringer Ingelheim International Gmbh Neue verbindungen
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012064911A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Piperidinone carboxamide indane cgrp receptor antagonists
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US8895572B2 (en) 2010-12-22 2014-11-25 Merck Sharp & Dohme Corp. Fused heterocyclic indane carboxamide CGRP receptor antagonists
WO2013066360A1 (en) 2010-12-22 2013-05-10 Merck Sharp & Dohme Corp. Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
US8591944B2 (en) 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2685826B1 (en) 2011-03-18 2016-02-03 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
WO2013036861A1 (en) 2011-09-08 2013-03-14 Codexis, Inc Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
KR102061180B1 (ko) 2012-03-14 2019-12-31 머크 샤프 앤드 돔 코포레이션 비대칭 상 이동 촉매로서의 비스-4급 신코나 알칼로이드 염
US9833488B2 (en) 2012-04-25 2017-12-05 Centric Research Institute Sensitization composition and method of use
EP2846801B1 (en) 2012-05-09 2017-04-05 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2846798B1 (en) 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
EP2846799B1 (en) 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Spirolactam cgrp receptor antagonists
SMT202400324T1 (it) 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
BR112016005589B8 (pt) 2013-09-16 2023-04-18 Merck Sharp & Dohme Composição farmacêutica líquida, e, uso da mesma
WO2015120014A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
JP2017512757A (ja) 2014-02-24 2017-05-25 ウリゲン ファーマシューティカルズ、インコーポレイテッド 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
JP6673924B2 (ja) 2015-01-23 2020-03-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
MX2018003713A (es) 2015-09-24 2018-08-15 Teva Pharmaceuticals Int Gmbh Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
US20180092899A1 (en) 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190135927A1 (en) 2017-09-29 2019-05-09 Bhl Patent Holdings, Llc Migraine, headache, chronic pain treatment, and prophylaxis options
US20200353088A1 (en) * 2017-11-06 2020-11-12 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374518A1 (en) 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) * 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
MX2021008191A (es) 2019-01-20 2021-08-11 Biohaven Pharm Holding Co Ltd Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
AU2020259461A1 (en) 2019-04-18 2021-11-11 Allergan Sales, Llc CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
WO2021062282A1 (en) 2019-09-25 2021-04-01 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
MX2024010878A (es) 2022-03-09 2024-09-17 Allergan Pharmaceuticals Int Ltd Tratamiento preventivo de la migra?a.

Also Published As

Publication number Publication date
EP4188375A4 (en) 2024-07-24
JP2023535744A (ja) 2023-08-21
AU2021319090A1 (en) 2023-03-02
EP4188375A1 (en) 2023-06-07
US12090148B2 (en) 2024-09-17
BR112023001615A2 (pt) 2023-04-04
US20220031686A1 (en) 2022-02-03
WO2022026767A1 (en) 2022-02-03
MX2023001071A (es) 2023-05-12
CA3190176A1 (en) 2022-02-03
US20250186422A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
CN116390712A (zh) 治疗偏头痛
JP7183355B2 (ja) 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法
US20250177378A1 (en) Treatment of depression
AU2018342072B2 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
CN114712356A (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
CN110461319A (zh) 治疗癫痫发作紊乱和prader-willi综合征的方法
WO2023173005A2 (en) Preventive treatment of migraine
Khan et al. Safety and efficacy of zavegepant in treating migraine: a systematic review
WO2024102381A1 (en) Method of providing ecopipam therapy to a patient
US12383545B1 (en) Treatment of migraine
Ryan et al. Medications Indicated for Chronic Weight Management
HK40118509A (zh) 抑郁的治疗
HK40093158A (zh) 用於治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法
HK40080675A (en) Use of bupropion and dextromethorphan combinations for treating neurological disorders
HK40100385A (zh) 用於神经精神病症的抗抑郁剂和右美沙芬的组合
Gorodetzky et al. A Phase 3 Trial of Firdapse™ Tablets in Lambert-Eaton Myasthenic Syndrome
WALTERS PAUL G. YEH** KAREN SPRUYT** LOURDES M. DELROSSO

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination